| Literature DB >> 34408053 |
Denny John1, M S Narassima2, Jaideep Menon3,4, Jammy Guru Rajesh5, Amitava Banerjee6.
Abstract
OBJECTIVES: From the beginning of the COVID-19 pandemic, clinical practice and research globally have centred on the prevention of transmission and treatment of the disease. The pandemic has had a huge impact on the economy and stressed healthcare systems worldwide. The present study estimates disability-adjusted life years (DALYs), years of potential productive life lost (YPPLL) and cost of productivity lost (CPL) due to premature mortality and absenteeism secondary to COVID-19 in the state of Kerala, India.Entities:
Keywords: COVID-19; health economics; health policy
Mesh:
Year: 2021 PMID: 34408053 PMCID: PMC8375445 DOI: 10.1136/bmjopen-2021-049619
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Parameters used in the study
| Parameters | Value | Sensitivity analysis* | Reference | End date | |
| Number of cases | 10% (S12), 20% (S13) and 30% (S14) increase in infected cases |
| 20 August 2020 | ||
| Actual | 52 199 | ||||
| Valid records | 44 554 | ||||
| Number of deaths | 10% (S18), 20% (S19) and 30% (S20) increase in deaths |
| 10 June 2021 | ||
| Actual | 1869 | ||||
| Valid records | 1841 | ||||
| Quarantine | 10% (S15), 20% (S16) and 30% (S17) increase in mild cases |
| 29 August 2020 | ||
| Home (mild cases) | 158 543 | ||||
| Hospital | 14 646 | – | |||
| Severity (%) |
| NA | |||
| Moderate | 80 | ||||
| Severe/critical | 20 | ||||
| Disability weights (average: S3, S4, S5) (lower: S6, S7, S8; upper: S9, S10, S11): three methods of disability weight calculation in each case ( |
| NA | |||
| Whooping cough | 0.051 | (0.032, 0.074) | |||
| Severe paratyphoid fever | 0.133 | (0.088, 0.19) | |||
| Asthma | 0.043 | (0.036, 0.05) | |||
| Moderate iron deficiency anaemia | 0.052 | (0.034, 0.076) | |||
| Mild diarrhoeal diseases | 0.074 | (0.049, 0.104) | |||
| Mild symptomatic peptic ulcer disease without anaemia | 0.011 | (0.005, 0.021) | |||
| Pharyngitis | 0.070 | (0.07, 0.07) | |||
| Symptomatic tension-type headache | 0.037 | (0.022, 0.057) | |||
| Moderate angina due to ischaemic heart disease | 0.080 | (0.052, 0.113) | |||
| Moderate symptomatic peptic ulcer disease with mild anaemia | 0.118 | (0.081, 0.163) | |||
| Other moderate mental disorders | 0.133 | (0.091, 0.186) | |||
| Life expectancy for age–gender cohort | 25% (S1) and 50% (S2) decrease |
| NA | ||
| Burden of isolation after discharge/recovery | 0 | 2-week isolation (S21) |
| NA | |
|
|
| Available for 1012 patients | |||
|
|
|
|
| ||
| 0–1 | 13.00 | 45 to 50 | 13.49 | ||
| 1–5 | 17.55 | 50 to 55 | 15.55 | ||
| 5–10 | 14.40 | 55 to 60 | 13.57 | ||
| 10–15 | 15.59 | 60 to 65 | 13.61 | ||
| 15–20 | 13.94 | 65 to 70 | 18.94 | ||
| 20–25 | 13.82 | 70 to 75 | 15.00 | ||
| 25–30 | 13.16 | 75 to 80 | 11.57 | ||
| 30–35 | 14.07 | 80 to 85 | 15.00 | ||
| 35–40 | 13.54 | 85+ | 17.33 | ||
| 40–45 | 15.26 | ||||
|
|
| NA | |||
|
|
|
| |||
| 0–1 | 72.5 | 77.9 | |||
| 1–5 | 72.3 | 77.8 | |||
| 5–10 | 68.4 | 73.9 | |||
| 10–15 | 63.4 | 69.0 | |||
| 15–20 | 58.6 | 64.1 | |||
| 20–25 | 53.7 | 59.2 | |||
| 25–30 | 48.9 | 54.4 | |||
| 30–35 | 44.2 | 49.5 | |||
| 35–40 | 39.5 | 44.7 | |||
| 40–45 | 34.8 | 39.9 | |||
| 45–50 | 30.3 | 35.1 | |||
| 50–55 | 25.9 | 30.5 | |||
| 55–60 | 21.8 | 26.2 | |||
| 60–65 | 17.9 | 21.9 | |||
| 65–70 | 14.3 | 17.9 | |||
| 70–75 | 11.4 | 14.3 | |||
| 75–80 | 8.6 | 11.0 | |||
| 80–85 | 6.2 | 7.9 | |||
| 85+ | 4.5 | 5.6 | |||
| Discount rate for value of life (%) | 2.90 | – |
| NA | |
| Age–gender population |
| – |
| NA | |
| Age–gender working population | |||||
| Discount rate (financial benchmark) (%) | 4.25 | – |
| 6 November 2020 | |
| Stay in intensive care unit (days) | 8 | – |
| NA | |
| Retirement age in Kerala (years) | 56 | – |
| NA | |
| Number of working days in a week | 6 | – |
| NA | |
| Per capita gross domestic product in Kerala | 221 904 rupees/year | – |
| 2020 | |
*Scenarios for the sensitivity analysis have been denoted by S1–S21. A detailed description is provided in online supplemental table SIV.
NA, not applicable.
DALY estimates for the baseline scenario (scenario 3)
| Age | DALYs until 15 November 2020 | DALYs until 10 June 2021 | ||||||
| Discounted | Undiscounted | Discounted | Undiscounted | |||||
| Male | Female | Male | Female | Male | Female | Male | Female | |
| 0–1 | 30.3 | 61.8 | 72.6 | 155.9 | 63.7 | 64.8 | 145.1 | 155.9 |
| 1–5 | 0.4 | 0.4 | 0.4 | 0.4 | 50.7 | 19.7 | 72.7 | 0.4 |
| 5–10 | 0.3 | 0.3 | 0.3 | 0.3 | 47.4 | 15.5 | 68.7 | 0.3 |
| 10–15 | 58.4 | 30.1 | 127.2 | 69.3 | 114.1 | 80.5 | 190.6 | 138.3 |
| 15–20 | 57.0 | 58.6 | 117.8 | 128.6 | 265.0 | 200.8 | 469.4 | 385.0 |
| 20–25 | 137.3 | 113.8 | 269.7 | 237.5 | 590.7 | 465.0 | 1021.5 | 888.7 |
| 25–30 | 262.7 | 192.2 | 490.4 | 381.4 | 893.3 | 639.8 | 1517.3 | 1197.4 |
| 30–35 | 126.0 | 132.0 | 222.4 | 248.1 | 1583.7 | 1168.2 | 2653.4 | 2129.1 |
| 35–40 | 636.2 | 351.3 | 1067.8 | 626.3 | 3581.9 | 1862.3 | 5886.8 | 3263.6 |
| 40–45 | 899.7 | 189.7 | 1428.1 | 319.8 | 5050.7 | 2306.4 | 7900.9 | 3831.0 |
| 45–50 | 1150.2 | 507.0 | 1728.1 | 807.8 | 6874.1 | 4193.9 | 10 242.4 | 6634.4 |
| 50–55 | 1603.7 | 952.0 | 2280.2 | 1434.0 | 9240.0 | 5943.5 | 13 054.6 | 8906.5 |
| 55–60 | 2343.5 | 1413.5 | 3161.6 | 2017.8 | 11 231.3 | 8078.1 | 15 108.0 | 11 502.2 |
| 60–65 | 2639.5 | 1426.8 | 3383.5 | 1927.5 | 13 502.1 | 8690.6 | 17 273.9 | 11 716.8 |
| 65–70 | 2610.8 | 1089.5 | 3189.4 | 1396.5 | 11 711.3 | 7826.5 | 14 271.9 | 10 006.4 |
| 70–75 | 1669.8 | 983.4 | 1961.0 | 1201.3 | 9513.7 | 6775.0 | 11 160.8 | 8265.5 |
| 75–80 | 898.2 | 508.6 | 1014.8 | 594.0 | 5201.8 | 4080.8 | 5873.8 | 4763.0 |
| 80–85 | 556.2 | 430.7 | 607.6 | 482.0 | 2908.8 | 2637.2 | 3174.4 | 2946.8 |
| 85+ | 274.3 | 196.5 | 292.5 | 212.8 | 1428.5 | 1579.8 | 1521.0 | 1708.0 |
| Total | 15 954.5 | 8638.4 | 21 415.5 | 12 241.5 | 83 853.0 | 56 628.3 | 111 607.3 | 78 439.5 |
DALYs, disability-adjusted life years.
YPPLL and CPL (mortality and absenteeism) until 15 November 2020
| Age group | YPPLL | CPL: death | CPL: morbidity | |||
| Male | Female | Male | Female | Male | Female | |
| 15–19 | 8.02 | 16.04 | 200 004.28 | 144 074.81 | 1 308 538.75 | 325 006.38 |
| 20–24 | 43.05 | 25.83 | 5 009 096.46 | 849 735.38 | 13 824 381.71 | 2 252 069.57 |
| 25–29 | 81.38 | 54.25 | 15 385 047.11 | 2 675 078.71 | 28 999 248.30 | 3 130 470.52 |
| 30–34 | 46.07 | 46.07 | 9 543 101.81 | 2 934 692.41 | 32 044 805.25 | 4 055 127.61 |
| 35–39 | 197.61 | 107.79 | 41 717 765.16 | 8 623 040.56 | 28 976 931.25 | 4 149 430.14 |
| 40–49 | 646.28 | 215.43 | 135 448 141.17 | 17 470 735.95 | 48 999 357.83 | 9 131 773.54 |
| 50–59 | 301.17 | 146.91 | 56 477 423.96 | 9 138 644.00 | 30 872 800.27 | 6 134 611.07 |
| Total | 263 780 579.94 | 41 836 001.82 | 185 026 063.37 | 29 178 488.82 | ||
CPL, cost of productivity lost; YPPLL, years of potential productive life lost.
YPPLL and CPL (mortality and absenteeism) until 10 June 2021
| Age group | YPPLL | CPL: death | CPL: morbidity | |||
| Male | Female | Male | Female | Male | Female | |
| 16–20 | 65.17 | 48.88 | 1 625 265.52 | 439 040.27 | 102 297 314.03 | 23 652 339.15 |
| 21–25 | 165.51 | 130.67 | 19 259 902.22 | 4 298 973.72 | 886 623 358.12 | 140 085 916.15 |
| 26–30 | 282.14 | 200.23 | 53 340 135.18 | 9 872 885.34 | 1 831 188 038.59 | 187 207 907.26 |
| 31–35 | 552.34 | 395.84 | 114 409 861.84 | 25 214 693.78 | 1 875 906 232.92 | 243 394 778.33 |
| 36–40 | 1321.80 | 647.59 | 279 048 434.48 | 51 808 021.93 | 1 788 669 340.39 | 262 987 085.64 |
| 41–50 | 3994.98 | 2015.17 | 837 278 167.58 | 163 427 668.31 | 2 860 063 434.24 | 541 756 862.03 |
| 51–59 | 611.09 | 373.19 | 114 596 136.95 | 23 214 211.95 | 1 703 001 999.97 | 350 660 556.84 |
| Total | 1 419 557 903.76 | 278 275 495.29 | 11 047 749 718.26 | 1 749 745 445.40 | ||
Refer to online supplemental table SVII for incidence and deaths.
CPL, cost of productivity lost; YPPLL, years of potential productive life lost.
Figure 1Sensitivity analysis (15 November 2020): (A) effect of life expectancy on DALYs; (B) effect of increase in cases on YLDs; (C) effect of mild cases on YLDs; (D) effect of deaths on DALYs; (E) effect of isolation after recovery on YLDs; and (F) DALYs for all scenarios. DALYs, disability-adjusted life years; YLDs, years lived with disability.
Figure 2Sensitivity analysis (10 June 2021): (A) effect of life expectancy on DALYs; (B) effect of increase in cases on YLDs; (C) effect of mild cases on YLDs; (D) effect of deaths on DALYs; (E) effect of isolation after recovery on YLDs; and (F) DALYs for all scenarios. DALYs, disability-adjusted life years; YLDs, years lived with disability.